论文部分内容阅读
［目的］ 评价应用经皮射频消融治疗肺癌的疗效和安全性，并分析影响其预后的因素。［方法］ 将随访资料完整的51例肺癌患者纳入分析，应用经皮射频消融进行治疗，评价近期及远期疗效和治疗并发症。应用Kaplan-Meier法和多因素Cox模型分析全组患者的生存预后情况。［结果］ 全组患者获CR4例（7.8%），PR 31例(60.8%)，SD 11例(21.6％)，PD 5例(9.8%)。疾病控制率为90.2%。随访0.5~3年，随访率为92.7％。0.5、1、2、3年的生存率分别为53％、32%、16％和4%，中位总生存时间(OS)为19.2个月。21例出现并发症，术中出现气胸１例，咯血3例。其他术后并发症包括胸部疼痛2例、术后发热15例。Cox多因素分析显示，肿瘤直径、临床分期、有无结合化疗和KPS评分是影响预后的独立因素。［结论］ 经皮射频消融治疗肺癌近期和远期疗效均较好，并发症可耐受；肿瘤直径、KPS评分、临床分期、有无结合化疗可能是影响经皮射频消融治疗肺癌预后的因素。［目的］ 评价应用经皮射频消融治疗肺癌的疗效和安全性，并分析影响其预后的因素。［方法］ 将随访资料完整的51例肺癌患者纳入分析，应用经皮射频消融进行治疗，评价近期及远期疗效和治疗并发症。应用Kaplan-Meier法和多因素Cox模型分析全组患者的生存预后情况。［结果］ 全组患者获CR4例（7.8%），PR 31例(60.8%)，SD 11例(21.6％)，PD 5例(9.8%)。疾病控制率为90.2%。随访0.5~3年，随访率为92.7％。0.5、1、2、3年的生存率分别为53％、32%、16％和4%，中位总生存时间(OS)为19.2个月。21例出现并发症，术中出现气胸１例，咯血3例。其他术后并发症包括胸部疼痛2例、术后发热15例。Cox多因素分析显示，肿瘤直径、临床分期、有无结合化疗和KPS评分是影响预后的独立因素。［结论］ 经皮射频消融治疗肺癌近期和远期疗效均较好，并发症可耐受；肿瘤直径、KPS评分、临床分期、有无结合化疗可能是影响经皮射频消融治疗肺癌预后的因素。
[Objective] To evaluate the efficacy and safety of percutaneous radiofrequency ablation in the treatment of lung cancer and to analyze the factors influencing its prognosis. [Methods] Fifty-one patients with lung cancer with follow-up data were included in the analysis, and percutaneous radiofrequency ablation was used to evaluate the short-term and long-term effects and the treatment of complications. The Kaplan-Meier method and multivariate Cox model were used to analyze the prognosis of all patients. [Results] All patients were CR4 (7.8%), PR 31 (60.8%), SD 11 (21.6%) and PD 5 (9.8%). Disease control rate was 90.2%. Follow-up 0.5 to 3 years, the follow-up rate was 92.7%. The survival rates at 0.5, 1, 2, and 3 years were 53%, 32%, 16%, and 4%, respectively. The median overall survival (OS) was 19.2 months. 21 cases of complications, pneumothorax occurred in 1 case, hemoptysis in 3 cases. Other postoperative complications included chest pain in 2 cases and postoperative fever in 15 cases. Cox multivariate analysis showed that tumor diameter, clinical stage, with or without chemotherapy and KPS scores were independent prognostic factors. [Conclusion] The percutaneous radiofrequency ablation of lung cancer has good short-term and long-term curative effect, and the complications can be tolerated. The tumor diameter, KPS score, clinical stage, with or without chemotherapy may be the factors influencing the prognosis of lung cancer by percutaneous radiofrequency ablation. [Objective] To evaluate the efficacy and safety of percutaneous radiofrequency ablation in the treatment of lung cancer and to analyze the factors influencing its prognosis. [Methods] Fifty-one patients with lung cancer with follow-up data were included in the analysis, and percutaneous radiofrequency ablation was used to evaluate the short-term and long-term effects and the treatment of complications. The Kaplan-Meier method and multivariate Cox model were used to analyze the prognosis of all patients. [Results] All patients were CR4 (7.8%), PR 31 (60.8%), SD 11 (21.6%) and PD 5 (9.8%). Disease control rate was 90.2%. Follow-up 0.5 to 3 years, the follow-up rate was 92.7%. The survival rates at 0.5, 1, 2, and 3 years were 53%, 32%, 16%, and 4%, respectively. The median overall survival (OS) was 19.2 months. 21 cases of complications, pneumothorax occurred in 1 case, hemoptysis in 3 cases. Other postoperative complications included chest pain in 2 cases and postoperative fever in 15 cases. Cox multivariate analysis showed that tumor diameter, clinical stage, with or without chemotherapy and KPS scores were independent prognostic factors. [Conclusion] The percutaneous radiofrequency ablation of lung cancer has good short-term and long-term curative effect, and the complications can be tolerated. The tumor diameter, KPS score, clinical stage, with or without chemotherapy may be the factors influencing the prognosis of lung cancer by percutaneous radiofrequency ablation.